A Phase 2/3 interventional study of Frespaciguat and Placebo to Frespaciguat in Pulmonary Arterial Hypertension and Hypertension, Pulmonary, sponsored by Merck Sharp & Dohme LLC. Completed at 91 sites in 18 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-05-25.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Pulmonary Arterial Hypertension by Merck & Co., Inc — 3 open to participants now, 5 under way, 1 of them phase 3. Pulmonary Arterial Hypertension · Merck & Co., Inc.
Among the 17 studies in Pulmonary Arterial Hypertension by Merck & Co., Inc, this one is the 5th largest by enrollment, is one of 4 that started in 2021, is the only one in phase 2/3, and was the 8th registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →3 of the 17 studies in Pulmonary Arterial Hypertension by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in India
Ages 18+
Merck Sharp & Dohme LLC · Sites in Japan
Ages 1–17
Merck Sharp & Dohme LLC · Sites in United States, Australia, Colombia and 9 more countries
Ages 1–17
By country, each count listing its studies:
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 6 · Phase 4 1
First in 2013; this study’s year is marked. 4 started in 2021.
This study's enrollment of 168 is above the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 46 across the 17 interventional studies. Of the 12 that completed or were terminated, 11 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Pulmonary Arterial Hypertension by Merck & Co., Inc, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a two-part (Phase 2/Phase 3) study of frespaciguat, an inhaled soluble guanylate cyclase stimulator, in participants with pulmonary arterial hypertension (PAH).
The first part (Phase 2) will assess three different doses of frespaciguat compared to placebo in a base period of 12 weeks, followed by comparison of three different doses of frespaciguat during an optional 40 month extension period. The treatment dose with the best efficacy and safety profile in the phase 2 cohort base period will be selected for use in the second part (Phase 3) of the study. The primary hypothesis of Phase 2 is that at least one frespaciguat dose is superior to placebo in reducing pulmonary vascular resistance (PVR) from baseline at week 12.
The purpose of the second part (Phase 3) of the study is to confirm the efficacy, safety, and tolerability of frespaciguat at the selected dose compared to placebo during a 12 week base period followed by an extension period of up to 5 years. The primary hypothesis of Phase 3 is that frespaciguat is superior to placebo in increasing 6-minute walk distance (6MWD) from baseline at week 12. Due to sponsor's decision this phase/part was not conducted.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Pulmonary arterial hypertension (PAH) in one of the following groups:
Eligibility RHC meeting all of the following criteria:
Exclusion Criteria:
PAH in one of the following groups:
Evidence or history of left heart disease, including any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive frespaciguat 380 µg via oral inhalation once daily for 12 week base period and for optional 40 month extension period.
Drug: Frespaciguat
Participants receive frespaciguat 100 µg via oral inhalation once daily for 12 week base period and for optional 40 month extension period.
Drug: Frespaciguat
Participants receive frespaciguat 32 µg via oral inhalation once daily for 12 week base period and for optional 40 month extension period.
Drug: Frespaciguat
Participants receive placebo via oral inhalation once daily for 12 week base period, and one of the MK-5475 doses (380, 100, or 32 µg) for the optional 40 month extension period.
Drug: Placebo to Frespaciguat
Participants receive one of 3 frespaciguat doses (380, 100 or 32 µg) to be selected at end of the Phase 2 Cohort, administered via oral inhalation once daily for 12-week base period and up to 40 months in the extension period
Drug: Frespaciguat
Participants receive placebo via oral inhalation once daily for 12 week base period and up to 40 months in the extension period.
Drug: Placebo to Frespaciguat
Frespaciguat (soluble guanylate cyclase stimulator) 380 µg, 100 µg or 32 µg administered as dry powder inhalation
Placebo administered as dry powder inhalation
Phase 2 Cohort: Mean Percent Change From Baseline in Pulmonary Vascular Resistance (PVR) at 12 Weeks
PVR was calculated in participants after MK-5475 dosing at baseline and Week 12. PVR is assessed by right heart catheterization (RHC). Based on the variables obtained by right heart catheterization (RHC), the percentage change from baseline PVR was calculated. Per protocol, this outcome measure was assessed only for base period and was not assessed during extension period.
Time frame: At baseline and 12 weeks
Phase 3 Cohort: Mean Change From Baseline in 6-Minute Walk Distance (6MWD) at 12 Weeks
6MWD is measured by an exercise test known as 6-Minute Walk Test (6MWT) that assesses functional capacity. It measures the distance covered over a time of 6 minutes and is intended to be used as an outcome measure by which to compare changes in excercise capacity. Each participant's 6MWD is to be measured at baseline and at 12 weeks. An increase in the distance walked during the 6MWT indicates improvement in functional exercise capacity.
Time frame: At baseline and 12 weeks
Phase 2 Cohort: Mean Change From Baseline in 6-Minute Walk Distance (6MWD) at 12 Weeks
6MWD is measured by an exercise test known as 6-Minute Walk Test (6MWT) that assesses functional capacity. It measures the distance covered over a time of 6 minutes and is used as an outcome measure by which to compare changes in exercise capacity. Each participant's 6MWD was measured at baseline and at 12 weeks. An increase in the distance walked during the 6MWT indicates improvement in functional exercise capacity.
Time frame: At baseline and 12 weeks
Phase 2 Cohort: Mean Change From Baseline in Mean Right Atrial Pressure (mRAP) at 12 Weeks
mRAP is the blood pressure in the right atrium of the heart. mRAP was assessed by right heart catheterization (RHC).A decrease in mRAP indicates improvement in right ventricular function, reduction of PAH related morbidity.
Time frame: At baseline and 12 weeks
Phase 2 Cohort: Mean Change From Baseline in Cardiac Index (CI) at 12 Weeks
The cardiac index (CI) is a hemodynamic measure that represents the cardiac output (CO) of an individual divided by their body surface area (BSA). Cardiac index is assessed by right heart catheterization (RHC). An increase in CI is indicates better right ventricular function and is associated with a reduction of PAH related morbidity and mortality.
Time frame: At baseline and 12 weeks
Phase 2 Cohort: Mean Change From Baseline in Stroke Volume Index (SVI) at 12 Weeks
The stroke volume index represents the amount of blood in mL, per square meter of body surface area, that is mobilized with each heart beat. SVI is assessed by RHC. An increase in SVI indicates better right ventricular function and is associated with a reduction of PAH related morbidity and mortality.
Time frame: At baseline and 12 weeks
Phase 3 Cohort: Mean Change From Baseline in 6-Minute Walk Distance (6MWD) at 24 Weeks
6MWD is measured by an exercise test known as 6-Minute Walk Test (6MWT) that assesses functional capacity. It measures the distance covered over a time of 6 minutes and is intended to be used as an outcome measure by which to compare changes in exercise capacity. Each participant's 6MWD is to be measured at baseline and at 24 weeks. An increase in the distance walked during the 6MWT indicates improvement in functional exercise capacity.
Time frame: At baseline and 24 weeks
Phase 3 Cohort: Proportion of Participants Whose World Health Organization Functional Class (WHO-FC) is Not Worse at 12 Week Relative to Baseline
The World Health Organization (WHO) classification of functional status is a measure of disease severity, based on a patient's description of their level of functioning and symptoms of disease in relation to their everyday activity. Patients were to be assigned 1 of 4 WHO-FC, dependent on limits of physical activity. As WHO-FC increases from I to IV, limits of physical activity were to increase.
Time frame: At baseline and 12 weeks
Phase 2 Cohort: Number of Participants Who Experienced an Adverse Event
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
Time frame: Up to approximately 2.25 years
Phase 2 Cohort: Number of Participants Who Discontinued Study Drug Due to an Adverse Event
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued treatment due to an AE was assessed.
Time frame: Up to approximately 2.25 years
Phase 3 Cohort: Number of Participants Who Experienced an Adverse Event
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
Time frame: Up to approximately 2.25 years
Phase 3 Cohort: Number of Participants Who Discontinued Study Drug Due to an AE
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued treatment due to an AE was assessed.
Time frame: Up to approximately 2.25 years
| Milestone | Base Period: Placebo | Base Period: MK-5475 32 µg | Base Period: MK-5475 100 µg | Base Period: MK-5475 380 µg | Extension Period: MK-5475 32 µg | Extension Period: MK-5475 100 µg | Extension Period: MK-5475 380 μg |
|---|---|---|---|---|---|---|---|
| Started | 41 | 42 | 44 | 41 | 0 | 0 | 0 |
| Completed | 39 | 41 | 43 | 41 | 0 | 0 | 0 |
| Not completed | 2 | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Base Period: Placebo | Base Period: MK-5475 32 µg | Base Period: MK-5475 100 µg | Base Period: MK-5475 380 µg | Extension Period: MK-5475 32 µg | Extension Period: MK-5475 100 µg | Extension Period: MK-5475 380 μg |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 45 | 46 | 44 |
| Completed | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 44 | 46 | 44 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 1 | 0 | 2 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Sponsors decision | 0 | 0 | 0 | 0 | 41 | 40 | 40 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 5 | 2 |
PVR was calculated in participants after MK-5475 dosing at baseline and Week 12. PVR is assessed by right heart catheterization (RHC). Based on the variables obtained by right heart catheterization (RHC), the percentage change from baseline PVR was calculated. Per protocol, this outcome measure was assessed only for base period and was not assessed during extension period.
| Percentage Change | Base Period: Placebo | Base Period: MK-5475 32 µg | Base Period: MK-5475 100 µg | Base Period: MK-5475 380 µg |
|---|---|---|---|---|
| Phase 2 Cohort: Mean Percent Change From Baseline in Pulmonary Vascular Resistance (PVR) at 12 Weeks | 4.3 ± 4.45 | -4.9 ± 4.07 | -17.6 ± 4.07 | -15.6 ± 5.39 |
6MWD is measured by an exercise test known as 6-Minute Walk Test (6MWT) that assesses functional capacity. It measures the distance covered over a time of 6 minutes and is intended to be used as an outcome measure by which to compare changes in excercise capacity. Each participant's 6MWD is to be measured at baseline and at 12 weeks. An increase in the distance walked during the 6MWT indicates improvement in functional exercise capacity.
No measurements were reported for this outcome.
6MWD is measured by an exercise test known as 6-Minute Walk Test (6MWT) that assesses functional capacity. It measures the distance covered over a time of 6 minutes and is used as an outcome measure by which to compare changes in exercise capacity. Each participant's 6MWD was measured at baseline and at 12 weeks. An increase in the distance walked during the 6MWT indicates improvement in functional exercise capacity.
| Meters | Base Period: Placebo | Base Period: MK-5475 32 µg | Base Period: MK-5475 100 µg | Base Period: MK-5475 380 µg |
|---|---|---|---|---|
| Phase 2 Cohort: Mean Change From Baseline in 6-Minute Walk Distance (6MWD) at 12 Weeks | 24.6 ± 66.3 | 27.4 ± 53.1 | 10.8 ± 45.6 | 11.3 ± 38.9 |
mRAP is the blood pressure in the right atrium of the heart. mRAP was assessed by right heart catheterization (RHC).A decrease in mRAP indicates improvement in right ventricular function, reduction of PAH related morbidity.
| Millimeters of Mercury (mmHg) | Base Period: Placebo | Base Period: MK-5475 32 µg | Base Period: MK-5475 100 µg | Base Period: MK-5475 380 µg |
|---|---|---|---|---|
| Phase 2 Cohort: Mean Change From Baseline in Mean Right Atrial Pressure (mRAP) at 12 Weeks | 0.3 (-8.0 to 9.0) | 0.3 (-17.0 to 7.0) | -0.5 (-8.0 to 14.0) | -0.1 (-14.0 to 12.0) |
The cardiac index (CI) is a hemodynamic measure that represents the cardiac output (CO) of an individual divided by their body surface area (BSA). Cardiac index is assessed by right heart catheterization (RHC). An increase in CI is indicates better right ventricular function and is associated with a reduction of PAH related morbidity and mortality.
| Liter/minutes/meter square (L/min/m^2) | Base Period: Placebo | Base Period: MK-5475 32 µg | Base Period: MK-5475 100 µg | Base Period: MK-5475 380 µg |
|---|---|---|---|---|
| Phase 2 Cohort: Mean Change From Baseline in Cardiac Index (CI) at 12 Weeks | 0.1 (-0.9 to 3.1) | 0.0 (-1.7 to 1.4) | 0.2 (-1.4 to 1.5) | 0.1 (-1.6 to 1.8) |
The stroke volume index represents the amount of blood in mL, per square meter of body surface area, that is mobilized with each heart beat. SVI is assessed by RHC. An increase in SVI indicates better right ventricular function and is associated with a reduction of PAH related morbidity and mortality.
| mL/beat/m^2 | Base Period: Placebo | Base Period: MK-5475 32 µg | Base Period: MK-5475 100 µg | Base Period: MK-5475 380 µg |
|---|---|---|---|---|
| Phase 2 Cohort: Mean Change From Baseline in Stroke Volume Index (SVI) at 12 Weeks | 2.9 (-9.3 to 44.4) | 0.2 (-37.2 to 20.7) | 3.2 (-21.8 to 35.2) | 1.2 (-29.1 to 25.1) |
6MWD is measured by an exercise test known as 6-Minute Walk Test (6MWT) that assesses functional capacity. It measures the distance covered over a time of 6 minutes and is intended to be used as an outcome measure by which to compare changes in exercise capacity. Each participant's 6MWD is to be measured at baseline and at 24 weeks. An increase in the distance walked during the 6MWT indicates improvement in functional exercise capacity.
No measurements were reported for this outcome.
The World Health Organization (WHO) classification of functional status is a measure of disease severity, based on a patient's description of their level of functioning and symptoms of disease in relation to their everyday activity. Patients were to be assigned 1 of 4 WHO-FC, dependent on limits of physical activity. As WHO-FC increases from I to IV, limits of physical activity were to increase.
No measurements were reported for this outcome.
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
| Participants | Base Period: Placebo | Base Period: MK-5475 32 µg | Base Period: MK-5475 100 µg | Base Period: MK-5475 380 µg | Extension Period: MK-5475 32 µg | Extension Period: MK-5475 100 µg | Extension Period: MK-5475 380 μg |
|---|---|---|---|---|---|---|---|
| Phase 2 Cohort: Number of Participants Who Experienced an Adverse Event | 27 | 28 | 28 | 27 | 33 | 38 | 39 |
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued treatment due to an AE was assessed.
| Participants | Base Period: Placebo | Base Period: MK-5475 32 µg | Base Period: MK-5475 100 µg | Base Period: MK-5475 380 µg | Extension Period: MK-5475 32 µg | Extension Period: MK-5475 100 µg | Extension Period: MK-5475 380 μg |
|---|---|---|---|---|---|---|---|
| Phase 2 Cohort: Number of Participants Who Discontinued Study Drug Due to an Adverse Event | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
No measurements were reported for this outcome.
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued treatment due to an AE was assessed.
No measurements were reported for this outcome.
Collected over Up to approximately 37 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Base Period: Placebo | 2/41 (4.9%) | 5/41 (12.2%) | 18/41 (43.9%) |
| Base Period: MK-5475 32 µg | 0/42 (0%) | 4/42 (9.5%) | 22/42 (52.4%) |
| Base Period: MK-5475 100 µg | 1/44 (2.3%) | 3/44 (6.8%) | 23/44 (52.3%) |
| Base Period: MK-5475 380 µg | 0/41 (0%) | 4/41 (9.8%) | 21/41 (51.2%) |
| Extension Period: Placebo to MK-5475 32 µg | 1/11 (9.1%) | 3/11 (27.3%) | 7/11 (63.6%) |
| Extension Period: Placebo to MK-5475 100 µg | 0/9 (0%) | 2/9 (22.2%) | 7/9 (77.8%) |
| Extension Period: Placebo to MK-5475 380 µg | 0/10 (0%) | 4/10 (40%) | 8/10 (80%) |
| Extension Period: MK-5475 32 µg | 0/34 (0%) | 5/34 (14.7%) | 24/34 (70.6%) |
| Extension Period: MK-5475 100 µg | 0/37 (0%) | 4/37 (10.8%) | 28/37 (75.7%) |
| Extension Period: MK-5475 380 μg | 2/34 (5.9%) | 11/34 (32.4%) | 28/34 (82.4%) |
| Event | Base Period: Placebo | Base Period: MK-5475 32 µg | Base Period: MK-5475 100 µg | Base Period: MK-5475 380 µg | Extension Period: Placebo to MK-5475 32 µg | Extension Period: Placebo to MK-5475 100 µg | Extension Period: Placebo to MK-5475 380 µg | Extension Period: MK-5475 32 µg | Extension Period: MK-5475 100 µg | Extension Period: MK-5475 380 μg |
|---|---|---|---|---|---|---|---|---|---|---|
| Device leakageProduct Issues | 0/41 | 0/42 | 0/44 | 0/41 | 2/11 | 0/9 | 0/10 | 0/34 | 0/37 | 0/34 |
| Cardiac failureCardiac disorders | 0/41 | 0/42 | 0/44 | 0/41 | 0/11 | 1/9 | 0/10 | 0/34 | 0/37 | 0/34 |
| PancreatitisGastrointestinal disorders | 0/41 | 0/42 | 0/44 | 0/41 | 0/11 | 1/9 | 0/10 | 0/34 | 0/37 | 0/34 |
| Multiple organ dysfunction syndromeGeneral disorders | 0/41 | 0/42 | 0/44 | 0/41 | 0/11 | 1/9 | 0/10 | 0/34 | 0/37 | 0/34 |
| Vulvovaginal wartsNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/41 | 0/42 | 0/44 | 0/41 | 0/11 | 1/9 | 0/10 | 0/34 | 0/37 | 0/34 |
| Atrial flutterCardiac disorders | 1/41 | 0/42 | 0/44 | 0/41 | 0/11 | 0/9 | 1/10 | 0/34 | 0/37 | 1/34 |
| Complication associated with deviceGeneral disorders | 0/41 | 1/42 | 0/44 | 0/41 | 0/11 | 0/9 | 1/10 | 0/34 | 0/37 | 0/34 |
| COVID-19Infections and infestations | 0/41 | 0/42 | 0/44 | 0/41 | 0/11 | 0/9 | 1/10 | 0/34 | 0/37 | 0/34 |
| COVID-19 pneumoniaInfections and infestations | 0/41 | 0/42 | 0/44 | 0/41 | 0/11 | 0/9 | 1/10 | 0/34 | 1/37 | 0/34 |
| Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/41 | 0/42 | 0/44 | 0/41 | 0/11 | 0/9 | 1/10 | 0/34 | 0/37 | 0/34 |
| Event | Base Period: Placebo | Base Period: MK-5475 32 µg | Base Period: MK-5475 100 µg | Base Period: MK-5475 380 µg | Extension Period: Placebo to MK-5475 32 µg | Extension Period: Placebo to MK-5475 100 µg | Extension Period: Placebo to MK-5475 380 µg | Extension Period: MK-5475 32 µg | Extension Period: MK-5475 100 µg | Extension Period: MK-5475 380 μg |
|---|---|---|---|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 0/41 | 1/42 | 3/44 | 3/41 | 1/11 | 1/9 | 3/10 | 5/34 | 6/37 | 6/34 |
| Accidental overdoseInjury, poisoning and procedural complications | 1/41 | 3/42 | 2/44 | 1/41 | 0/11 | 0/9 | 0/10 | 8/34 | 2/37 | 3/34 |
| DiarrhoeaGastrointestinal disorders | 3/41 | 2/42 | 2/44 | 3/41 | 0/11 | 2/9 | 2/10 | 1/34 | 1/37 | 2/34 |
| Oral candidiasisInfections and infestations | 0/41 | 0/42 | 0/44 | 0/41 | 1/11 | 2/9 | 0/10 | 0/34 | 0/37 | 0/34 |
| Upper respiratory tract infectionInfections and infestations | 1/41 | 1/42 | 2/44 | 0/41 | 2/11 | 2/9 | 0/10 | 4/34 | 4/37 | 4/34 |
| HeadacheNervous system disorders | 4/41 | 3/42 | 8/44 | 6/41 | 1/11 | 1/9 | 1/10 | 2/34 | 8/37 | 4/34 |
| NauseaGastrointestinal disorders | 0/41 | 1/42 | 3/44 | 3/41 | 2/11 | 0/9 | 2/10 | 2/34 | 3/37 | 1/34 |
| Oedema peripheralGeneral disorders | 0/41 | 0/42 | 0/44 | 0/41 | 1/11 | 1/9 | 2/10 | 1/34 | 0/37 | 0/34 |
| NasopharyngitisInfections and infestations | 1/41 | 1/42 | 1/44 | 1/41 | 2/11 | 1/9 | 2/10 | 0/34 | 5/37 | 2/34 |
| Neck painMusculoskeletal and connective tissue disorders | 1/41 | 0/42 | 0/44 | 0/41 | 0/11 | 0/9 | 2/10 | 0/34 | 0/37 | 0/34 |
| Age, Continuous(Years) | Base Period: Placebo | Base Period: MK-5475 32 µg | Base Period: MK-5475 100 µg | Base Period: MK-5475 380 µg | Total |
|---|---|---|---|---|---|
| Mean | 52.1 ± 12.7 | 48.1 ± 16.9 | 51.7 ± 14.2 | 47.6 ± 15.9 | 49.9 ± 15.0 |
| Sex: Female, Male(Participants) | Base Period: Placebo | Base Period: MK-5475 32 µg | Base Period: MK-5475 100 µg | Base Period: MK-5475 380 µg | Total |
|---|---|---|---|---|---|
| Female | 28 | 34 | 32 | 30 | 124 |
| Male | 13 | 8 | 12 | 11 | 44 |
| Ethnicity (NIH/OMB)(Participants) | Base Period: Placebo | Base Period: MK-5475 32 µg | Base Period: MK-5475 100 µg | Base Period: MK-5475 380 µg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 11 | 14 | 10 | 12 | 47 |
| Not Hispanic or Latino | 30 | 27 | 33 | 29 | 119 |
| Unknown or Not Reported | 0 | 1 | 1 | 0 | 2 |
| Race (NIH/OMB)(Participants) | Base Period: Placebo | Base Period: MK-5475 32 µg | Base Period: MK-5475 100 µg | Base Period: MK-5475 380 µg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 3 | 0 | 0 | 0 | 3 |
| Asian | 3 | 1 | 0 | 0 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 3 | 1 | 1 | 7 |
| White | 32 | 34 | 41 | 36 | 143 |
| More than one race | 1 | 4 | 2 | 4 | 11 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from May 2021 to primary completion in Jan 2024, 31 months.
Results were first posted in Feb 2025, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Frespaciguat
Pulmonary Arterial Hypertension →